LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

Home・Aktien・Innoviva Inc

Innoviva Inc

Geschlossen

BrancheGesundheitswesen

20.63 -1.76

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

20.58

Max

21.03

Schlüsselkennzahlen
By Trading Economics
Einkommen	26M 90M
Verkäufe	7.5M 108M
KGV Branchendurchschnitt	13.374 80.03
EPS	0.385
Gewinnspanne	83.403
Angestellte	127
EBITDA	25M 108M

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	+52.38% upside

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	519M 1.7B
Vorheriger Eröffnungskurs	22.39
Vorheriger Schlusskurs	20.63

Nachrichtenstimmung

By Acuity

50%

23 / 374 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Strong Bullish Evidence

18.57 / 18.75 Unterstützung & Widerstand

Innoviva Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

9. Dez. 2025, 22:13 UTC

Ergebnisse

GE Vernova Raises Outlook, Doubles Dividend on Energy Market Momentum

9. Dez. 2025, 21:40 UTC

Ergebnisse

GameStop Sales Fall as Collectibles Remain Only Bright Spot

9. Dez. 2025, 18:51 UTC

Akquisitionen, Fusionen, Übernahmen

Broadwood Partners Still Opposes Alcon's Higher Bid for Staar Surgical

9. Dez. 2025, 16:57 UTC

Wichtige Markttreiber

Clear Secure Rises on Medicare Identity Verification Contract

9. Dez. 2025, 23:46 UTC

Market Talk

Nikkei May Trade Rangebound Ahead of Fed Rate Decision -- Market Talk

9. Dez. 2025, 23:46 UTC

Akquisitionen, Fusionen, Übernahmen

Legend Holdings Stake in Lenovo Now at 32.34%

9. Dez. 2025, 23:45 UTC

Akquisitionen, Fusionen, Übernahmen

Legend Holdings: Remains Optimistic About Lenovo's Future Development Potential

9. Dez. 2025, 23:44 UTC

Akquisitionen, Fusionen, Übernahmen

Legend Holdings: Purchased Lenovo Shares at Average Price of HK$9.7653/Share

9. Dez. 2025, 23:43 UTC

Akquisitionen, Fusionen, Übernahmen

Legend Holdings: Acquired Lenovo Shares for Total Cash Consideration of HK$1.12B

9. Dez. 2025, 23:43 UTC

Akquisitionen, Fusionen, Übernahmen

Legend Holdings: Acquired 115.17M Lenovo Shares From Open Market Between Nov. 21 and Dec. 9

9. Dez. 2025, 23:35 UTC

Market Talk

Gold Edges Higher Ahead of FOMC Decision -- Market Talk

9. Dez. 2025, 22:42 UTC

Ergebnisse

PepsiCo Wants to Boost Sales, Cut Costs. The Street Is Doubtful. -- Barrons.com

9. Dez. 2025, 21:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

9. Dez. 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9. Dez. 2025, 21:48 UTC

Market Talk

Hiring Confidence Slips in Canada Entering 2026 -- Market Talk

9. Dez. 2025, 21:36 UTC

Ergebnisse

Casey's General Stores: Fiscal 2026 EBITDA Is Expected to Increase 15% to 17% >CASY

9. Dez. 2025, 21:36 UTC

Ergebnisse

Casey's General Stores: Total Inside Gross Profit Increased 13.5% to $703.4M Compared to Prior Yr >CASY

9. Dez. 2025, 21:36 UTC

Ergebnisse

Casey's General Stores: Now Expects Inside Same-Store Sales to Increase 3% to 4% and an Inside Margin of 41% to 42% >CASY

9. Dez. 2025, 21:36 UTC

Ergebnisse

Casey's General Stores: Same-Store Fuel Gallons Up 0.8% Compared to Prior Yr With Fuel Margin of 41.6 Cents per Gallon, Total Fuel Gross Profit Increased 20.9% to $377.4M Compared to Prior Yr >CASY

9. Dez. 2025, 21:36 UTC

Ergebnisse

Casey's General Stores: Inside Same-Store Sales Increased 3.3% Compared to Prior Yr, and 7.5% on 2-Yr Stack Basis, With an Inside Margin of 42.4% >CASY

9. Dez. 2025, 20:28 UTC

Market Talk

Oil Futures Decline for Second Straight Session -- Market Talk

9. Dez. 2025, 20:27 UTC

Akquisitionen, Fusionen, Übernahmen

Teck Resources: Merger of Equals With Anglo Amer Plc Approved by Both Classes of Teck Hldrs

9. Dez. 2025, 20:27 UTC

Akquisitionen, Fusionen, Übernahmen

Teck Reports Voting Results From Special Meeting of Hldrs

9. Dez. 2025, 20:26 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Moody's: Paramount's Warner Bid Makes Strategic Sense, With Risk -- Market Talk

9. Dez. 2025, 20:21 UTC

Market Talk

U.S. Natural Gas Extends Pullback on Shifting Weather Outlook -- Market Talk

9. Dez. 2025, 19:52 UTC

Ergebnisse

Correction to 58 S&P 500 Stocks Have Dividends Higher Than Treasuries. 10 Look Better Than Bonds. -- Barrons.com on Dec. 8

9. Dez. 2025, 19:17 UTC

Ergebnisse

Update: 58 S&P 500 Stocks Have Dividends Higher Than Treasuries. 10 Look Better Than Bonds. -- Barrons.com

9. Dez. 2025, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

9. Dez. 2025, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

9. Dez. 2025, 17:11 UTC

Ergebnisse

Nvidia Has Permission to Sell H200 Chips to China. Why It Might Not Matter Much for the Stock. -- Barrons.com

Peer-Vergleich

Kursveränderung

Innoviva Inc Prognose

Kursziel

By TipRanks

52.38% Vorteil

12-Monats-Prognose

Durchschnitt 32 USD 52.38%

Hoch 45 USD

Tief 17 USD

Basierend auf 4 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Innoviva Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

4 ratings

Buy

Halten

Sell

Basierend auf 4 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Innoviva Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

18.57 / 18.75Unterstützung & Widerstand

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Stimmung

By Acuity

23 / 374 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Innoviva Inc

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.